Mankind Pharma Inks Licensing Pact with Innovent

Mankind Pharma, a leading Indian multinational headquartered in Delhi, specialises in a wide range of therapeutic areas, including antibiotics, gastrointestinal, cardiovascular, dermatology, and erectile dysfunction treatments. In 2023, the company made a bold entry into the oncology space with its ₹1,872 crore acquisition of Panacea Biotec, marking a significant milestone in its growth journey.

Partnership Details

On December 26, 2024, Mankind Pharma announced a partnership with China’s Innovent Biologics to bring the advanced anti-cancer drug Sintilimab to India. Under an exclusive licensing agreement, Mankind Pharma will handle the registration, import, marketing, and distribution of Sintilimab, while Innovent will oversee manufacturing and supply. 

Marketed as TYVYT in China, Sintilimab is a cutting-edge PD-1 immunotherapy co-developed with Eli Lilly, designed to block the PD-1/PD-L1 pathway, reactivating T-cells to empower the immune system in fighting cancer effectively.

Sintilimab in India

As part of this partnership, Mankind Pharma aims to launch Sintilimab in India within 3 years and plans to price it competitively to ensure wider accessibility. The introduction of this revolutionary therapy aligns with Mankind Pharma’s vision of enhancing patient outcomes and bolstering its leadership in oncology.

Company Statement

“At Mankind Pharma, we are steadfast in our commitment to transforming cancer care in India. By introducing this innovative therapy, we reaffirm our dedication to improving the lives of patients and strengthening our foothold in the oncology space,” said Atish Majumdar, Senior President of Sales and Marketing at Mankind Pharma. 

He further highlighted the company’s expansive pharmaceutical expertise, supported by a robust distribution network comprising over 13,000 stockists and a formidable field force of 16,000 professionals across India.

Share Price Performance

At 2:59 PM, Mankind Pharma Ltd.’s share price was at ₹2,872.65 per share on the NSE.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in securities market are subject to market risks, read all the related documents carefully before investing.